Calcified and noncalcified coronary plaques and atherosclerotic cardiovascular bvents in patients with severe gypercholesterolemia-moving forward with risk stratification and therapy (2022)
- Autor:
- Autor USP: SANTOS FILHO, RAUL DIAS DOS - FM
- Unidade: FM
- DOI: 10.1001/jamanetworkopen.2021.48147
- Subjects: HIPERCOLESTEROLEMIA; ARTERIOSCLEROSE CORONÁRIA; EDITORIAL
- Language: Inglês
- Imprenta:
- Source:
- Título: Jama network open
- ISSN: 2574-3805
- Volume/Número/Paginação/Ano: v. 5, n. 2, article ID e2148147, 3p, 2022
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
SANTOS FILHO, Raul Dias dos. Calcified and noncalcified coronary plaques and atherosclerotic cardiovascular bvents in patients with severe gypercholesterolemia-moving forward with risk stratification and therapy. Jama network open. Chicago: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1001/jamanetworkopen.2021.48147. Acesso em: 27 jan. 2026. , 2022 -
APA
Santos Filho, R. D. dos. (2022). Calcified and noncalcified coronary plaques and atherosclerotic cardiovascular bvents in patients with severe gypercholesterolemia-moving forward with risk stratification and therapy. Jama network open. Chicago: Faculdade de Medicina, Universidade de São Paulo. doi:10.1001/jamanetworkopen.2021.48147 -
NLM
Santos Filho RD dos. Calcified and noncalcified coronary plaques and atherosclerotic cardiovascular bvents in patients with severe gypercholesterolemia-moving forward with risk stratification and therapy [Internet]. Jama network open. 2022 ; 5( 2):[citado 2026 jan. 27 ] Available from: https://doi.org/10.1001/jamanetworkopen.2021.48147 -
Vancouver
Santos Filho RD dos. Calcified and noncalcified coronary plaques and atherosclerotic cardiovascular bvents in patients with severe gypercholesterolemia-moving forward with risk stratification and therapy [Internet]. Jama network open. 2022 ; 5( 2):[citado 2026 jan. 27 ] Available from: https://doi.org/10.1001/jamanetworkopen.2021.48147 - Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps
- Characterizing familial chylomicronemia syndrome: baseline data of the APPROACH study
- Real-world outcomes with lomitapide use in paediatric patients with homozygous familial hypercholesterolaemia
- Sex disparity in the management and outcomes of dyslipidemia of diabetic patients in the Arabian Gulf: findings from the CEPHEUS study
- Vertebral bone density by quantitative computed tomography mirrors bone structure histomorphometric parameters in hemodialysis patients
- Effects of medication, treatment, and behavioral beliefs on intentions to take medication in patients with familial hypercholesterolemia
- Increased subclinical atherosclerosis burden in familial hypercholesterolemia phenotype [Editorial]: What do genetic defects tell us and what are the clinical implications?
- Sodium intake and prevalence of hypertension in elementary school students
- Clinical Genetic Testing for Familial Hypercholesterolemia
- Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: results from the SPIRE randomized trials of bococizumab
Informações sobre o DOI: 10.1001/jamanetworkopen.2021.48147 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
